Back

Distribution of GOPC:ROS1 and other ROS1 fusions in glioma types

Sievers, P.; Stichel, D.; Sill, M.; Schrimpf, D.; Sturm, D.; Selt, F.; Ecker, J.; Miele, E.; Kranendonk, M. E. G.; Tops, B. B. J.; Kohlhof-Meinecke, P.; Beschorner, R.; Kramm, C. M.; Hasselblatt, M.; Reifenberger, G.; Capper, D.; Wesseling, P.; Milde, T.; Korshunov, A.; Witt, O.; Pfister, S. M.; Wick, W.; von Deimling, A.; Jones, D. T. W.; Sahm, F.

2021-05-03 genomics
10.1101/2021.04.30.442173 bioRxiv
Show abstract

The ROS proto-oncogene 1 (ROS1) gene is rearranged in various cancers. The translated fusion protein presents an attractive therapeutic target, since specific inhibitors have been approved for several tumor types. In glioma, ROS1 fusions are frequent within infantile hemispheric glioma, and single case reports on occurrences in other glioma types exist. However, a comprehensive analysis spanning the full width of glioma types and subtypes is lacking. We here assessed the spectrum and distribution of ROS1 fusions by screening >20,000 glioma cases for typical chromosomal alterations, with subsequent RNA-sequencing for confirmation of candidate cases. ROS1 fusions were identified in 16 cases, from low grade pilocytic astrocytoma WHO grade 1 to glioblastoma, IDH wildtype WHO grade 4. Thus, despite being enriched in some tumor types, ROS1 fusions are not pathognomonic for specific glioma types and may consitute a relevant target in a variety of cases.

Matching journals

The top 4 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.